B. Metzler seel. Sohn & Co. Holding AG Invests $767,000 in Insmed Incorporated (NASDAQ:INSM)

B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of Insmed Incorporated (NASDAQ:INSM) in the 3rd quarter, Holdings Channel reports. The fund purchased 10,510 shares of the biopharmaceutical company’s stock, valued at approximately $767,000.

A number of other hedge funds also recently added to or reduced their stakes in INSM. Vanguard Group Inc. boosted its stake in shares of Insmed by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 14,509,235 shares of the biopharmaceutical company’s stock worth $393,636,000 after buying an additional 383,714 shares during the last quarter. Darwin Global Management Ltd. bought a new position in Insmed in the second quarter valued at about $237,076,000. Principal Financial Group Inc. boosted its position in Insmed by 12.9% in the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock worth $136,648,000 after purchasing an additional 214,130 shares during the last quarter. Clearbridge Investments LLC grew its stake in shares of Insmed by 76.8% during the 2nd quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock valued at $110,212,000 after purchasing an additional 714,539 shares during the period. Finally, Hood River Capital Management LLC increased its position in shares of Insmed by 36.7% during the 2nd quarter. Hood River Capital Management LLC now owns 1,315,392 shares of the biopharmaceutical company’s stock valued at $88,131,000 after purchasing an additional 352,891 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on INSM shares. StockNews.com downgraded shares of Insmed from a “hold” rating to a “sell” rating in a report on Friday, August 9th. Stifel Nicolaus lifted their price target on shares of Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. UBS Group upped their price objective on Insmed from $78.00 to $84.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. Finally, Bank of America upped their price target on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and an average target price of $83.67.

Insiders Place Their Bets

In other Insmed news, insider Michael Alexander Smith sold 27,871 shares of the firm’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the completion of the sale, the insider now owns 67,856 shares of the company’s stock, valued at $5,045,093.60. This trade represents a 29.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the transaction, the insider now directly owns 100,100 shares in the company, valued at approximately $7,157,150. This represents a 27.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 78,882 shares of company stock valued at $5,765,446 over the last three months. 4.60% of the stock is owned by company insiders.

Insmed Stock Down 0.9 %

Shares of NASDAQ INSM opened at $73.15 on Friday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $80.53. The firm’s 50-day moving average price is $72.04 and its 200-day moving average price is $66.03. The stock has a market capitalization of $13.09 billion, a price-to-earnings ratio of -13.18 and a beta of 1.12.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. Insmed’s revenue was up 18.1% on a year-over-year basis. During the same period last year, the firm earned ($1.10) earnings per share. On average, equities research analysts anticipate that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.